Session Details
JSNM Oral 2:Oncology 2: radionuclide therapy and novel radiopharmaceuticals
Thu. Nov 13, 2025 10:20 AM - 11:30 AM JST
Thu. Nov 13, 2025 1:20 AM - 2:30 AM UTC
Thu. Nov 13, 2025 1:20 AM - 2:30 AM UTC
Room 2（1F, Exhibition Hall 2 A, Kyoto International Exhibition Hall 'Miyako Messe'）
座長：東 達也（量子科学技術研究開発機構 量子医科学研究所）
[1-MO2-1]Safety of [211At] MABG in patients with pheochromocytoma or paraganglioma: A phase I study
Shozo Okamoto1、Shigeyasu Sugawara1,2、Masao Kobayakawa3、Kazuhiro Takahashi1、Kaori Nomura1、Noboru Oriuchi1、Hiroshi Ito2、Tohru Shiga1 (1.Advanced Clinical Research Center, Fukushima Medical University, Fukusimia Japan、2.Department of Radiology and Nuclear Medicine,、3.Medical Research Center, Fukushima Medical University)
[1-MO2-2]TAT against antibody treatment resistant peritoneal metastasis of uterine serous carcinoma
Huizi K. Li1、Mayuka Anko2、Sumitaka Hasegawa1 (1.Dept. of Charged Particle Therapy Res., QST、2.Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan)
[1-MO2-3]Evaluation of HMGB1 release associated with immune activation during 131I-MIBG therapy
Ririka Handa1、Kakeru Sato1,2、Taiga Watanabe1、Ryotaro Abe1、Jianwei Yao1、Yuna Hamada1、Jyunndai Yamagata1、Asuka Mizutani1、Hiroshi Wakabayashi3、Keiichi Kawai1,4、Masato Kobayashi1 (1.Division of Health Sciences,Graduate School of Medical Sciences,Kanazawa University,Ishikawa,Japan、2.Department of Radiology, University of Fukui Hospital, Fukui, Japan、3.Deparment of Nuclear Medicine, University of kanazawa Hospital, Ishikawa, Japan、4.Biomedical Imaging Research Center, Fukui University)
[1-MO2-4]Extended single-dose toxicity study of211At-MABG in normal mice
Songji Zhao1、Taiki Joho1、Naoyuki Ukon1、Saki Shimoyama1、Ken-ichi Nishijima1、Atsushi Yamashita1,2、Masao Kobayakawa3、Noboru Oriuchi1、Tohru Shiga1、Kazuhiro Takahashi1、Hiroshi Ito1,4 (1.Advanced Clinical Research Center, Hukushima Global Medical Science Center, Fukushima University, Fukushima, Japan、2.University of Miyazaki, Miyazaki, Japan、3.Fukushima Medical University, Fukushima, Japan、4.Fukushima Medical University, Fukushima, Japan)
[1-MO2-5]Prediction of tumor kinetics of Y-90 FAPI46 using Ga-68 FAPI PET CT
Masao Watanabe1,2、Walter Jentzen2、David Kersting2、Ken Herrmann2、Wolfgang P Fendler2、Pedro Fragoso Costa2 (1.Kyoto Univ. Rad.、2.Essen Univ, Nucl)
[1-MO2-6]Radiation-Induced GD2 Upregulation in Neuroblastoma: Implications for Combination Therapy
Xinzhu Yang1、Xue Zhang1、Zhuoqing Chen1、Vu Hoang Minh Chau1、Rie Kuroda2,3、Naotoshi Sugimoto4、Hiroshi Wakabayashi1、Seigo Kinuya1 (1.Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan、2.Department of Pediatrics, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan、3.Department of Pediatrics, Ishikawa Prefectural Central Hospital、4.Faculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Ishikawa, Japan)
[1-MO2-7]Combination of MAPK inhibitor to enhance the therapeutic effect of131I-MIBG
Taiga Watanabe1、Ririka Handa1、Ryotarou Abe1、Jianwei Yao1、Zinya Higashino1、Kakeru Satou1,2、Asuka Mizutani1、Hiroshi Wakabayashi3、Keiichi Kawai1,4、Masato Kobayashi1 (1.Division of Health Sciences, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan、2.University of Fukui Hospital, Department of Radiation, Fukui, Japan、3.University of Kanazawa Hospital, Department of Nuclear Medicine, Ishikawa, Japan、4.University of Fukui, Biomedical Imaging Reserch Center, Fukui, Japan)